OTLK

Fund-flow metrics are robust (7.27/10), with consistent positive trends across block, small, medium, and large orders, indicating buying interest despite the recent crash. Among three analysts, the consensus is neutral (66.7%) with one strong-buy; historical win rates for these calls are low, but the weighted rating remains cautiously optimistic. Together, capital inflows and analyst sentiment slightly offset the negative news flow, yet the stock's path will likely hinge on FDA-related developments.